ABVC BioPharma (ABVC) Q3 2025 earnings summary

Executive summary

• Q3 2025 revenue was $1.28 million, up 230% year-over-year, driven by milestone licensing revenue from OncoX, ForSeeCon, and strong CNS, ophthalmology, and oncology segments; nine-month revenue reached $795,950, a 57% increase from the prior year.

• Net loss for Q3 2025 was $1,287,523, a 164% increase from Q3 2024; nine-month net loss was $4,564,546, up 2% year-over-year.

• Total assets as of September 30, 2025, were $21.18 million, up 181% from year-end 2024, reflecting significant investments in property and equipment.

• The company completed full repayment of convertible notes with Lind Partners, reducing debt and potential dilution.

• Maintains an asset-light model focused on licensing, partnerships, and collaborative development.

Financial highlights

• Q3 2025 licensing revenue reached $1.28 million, up from $0.39 million in Q3 2024, a 230% increase year-over-year.

• Gross profit for Q3 2025 was $795,950, compared to $388,980 in Q3 2024; nine-month gross profit was $795,950, up from $506,860.

• Property and equipment (net) rose to $12.06 million from $0.51 million at year-end 2024, a 2,100% increase.

• Cash and cash equivalents as of September 30, 2025, were $192,068; restricted cash was $661,843.

• Working capital deficit as of September 30, 2025, was $2,434,951, improved from a $4,377,616 deficit at year-end 2024.

Outlook and guidance

• Management is focused on converting strategic investments into sustainable revenue through licensing, milestone payments, and expansion of CDMO services.

• Recent investments in Taiwan are expected to enhance future research and manufacturing capacity.

• The company anticipates ongoing affiliate integration and project execution will contribute positively to cash flows over the next 12 months.

• Plans include raising additional capital, controlling expenses, and reducing debt to address liquidity risks.

• Focus remains on advancing key pipeline assets and exploring additional partnerships for long-term growth.